Many of our consortium partners will be attending and participating ASN.
Have a look for more details on when and where to find us during ASN!
Please find the whole program here.
Thu, October 24
- 2:30 PM Room 6D – More Salt: Hypertonic Saline for Augmenting Diuresis – Steven Coca (Renalytix)
- 3:00 PM Clinical Practice Sessions Room 5 – Treatment of HFpEF in Patients with Kidney Diseases: Insights from Recent Clinical Trials – Hiddo Lambers Heerspink (UMCG)
- 4:30 to 6:00 PM Clinical Practice Session6 Room 33 (Convention Center):
- Ju et al., TH-OR47, title: Urinary Clusterin as a Pharmacodynamic Response Biomarker for the Endothelin Receptor Antagonist Atrasentan
- Moedt E et al., TH-OR52, title: Association of Urinary Epidermal Growth Factor with Kidney Outcomes and Effects of SGLT2 Inhibition: Results from the CANVAS and CREDENCE Trials
- Steven Coca (Renalytix), TH-OR49, Diabetic Kidney Disease – Clinical: Novel Insights into Precision Medicine [OR0702]
Fri, October 25
- 08:30 to 09:00 AM Hall D, Convention Center – ASN-AHA Donald W. Seldin Young Investigator Award and Address “Innovations in Clinical Trial Design and Conduct for New Therapeutic Approaches in CKD”- Hiddo Lambers Heerspink
- 10:00 AM to 12:00 PM Exhibit Hall B – Poster session FR-PO315 Steven Coca (Renalytix) – Diabetic Kidney Disease: Clinical Modeling, Diagnosis, Education, and More [PO0702-1]
- 10:00 AM to 12:00 PM Exhibit Hall B – Poster session by Andre de la Rambeije – Differences in Plasma Proteomic Profiles between Patients with and without Type 2 Diabetes and CKD: New insights from DAPA-CKD
- 11:15 to 11:30 AM – SMART trial – Hiddo Lambers Heerspink
- 11:30 PM, Room 6A – Use of SGLT2 Inhibitors, Endothelin Receptor Antagonists, and TargetedRelease Formulation Budesonide in IgAN – Pietro Canetta
Sat, October 26
- 10:00 AM to 12:00 PM Exhibit Hall B – Poster presentation by Andre De la Rambelje – Unraveling the mechanism of SGLT2i using urinary proteomics in patients with diabetic kidney disease [SA-PO321]
- 17:30 to 17:40 PM – SUCCED-2 trial – Hiddo Lambers Heerspink
